Efficacy of increasing donepezil in mild to moderate Alzheimer's disease patients who show a diminished response to 5mg donepezil: A preliminary study

Psychogeriatrics

Volumn 13, Issue 2, 2013, Pages 88-93

  Yatabe, Yusuke ^a   Hashimoto, Mamoru ^b   Kaneda, Keiichiro ^b   Honda, Kazuki ^b   Ogawa, Yusuke ^c   Yuuki, Seiji ^b   Ikeda, Manabu ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

^c KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Alzheimer's disease; Behavioural and psychological symptoms of dementia; Cognitive function; Donepezil; Dose escalation

Indexed keywords

DONEPEZIL;

AGED; ALZHEIMER DISEASE; ANOREXIA; ARTICLE; CAREGIVER BURDEN; CLINICAL ARTICLE; DEPRESSION; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTERVIEW; MALE; NAUSEA; POLLAKISURIA; PRIORITY JOURNAL; SUPRAVENTRICULAR PREMATURE BEAT;

ALZHEIMER'S DISEASE; BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA; COGNITIVE FUNCTION; DONEPEZIL; DOSE ESCALATION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CAREGIVERS; CHOLINESTERASE INHIBITORS; COGNITION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INDANS; JAPAN; MALE; MIDDLE AGED; PIPERIDINES; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84879029967     PISSN: 13463500     EISSN: 14798301     Source Type: Journal    
DOI: 10.1111/psyg.12004     Document Type: Article

References (24)

1. Homma A, Imai Y, Tago H etal. Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: results from a 24-week, double-blind, placebo-controlled, randomized trial. Dement Geriatr Cogn Disord 2008; 25: 399-407.
2. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944.
3. Folstein MF, Folstein SE, McHugh PR. 'Mini-mental state': a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
4. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry 1982; 140: 566-572.
5. Mohs RC, Rosen WG, Davis KL. The Alzheimer's Disease Assessment Scale; an instrument for assessing treatment efficacy. Psychopharmacol Bull 1983; 19: 448-450.
6. Honma A, Fukuzawa K, Tsukada Y, Ishii T, Hasegawa K, Mohs RC. Preparation of the Japanese version of the Alzheimer's Disease Assessment Scale (ADAS). J Jpn Psychogeriatr Soc 1992; 3: 647-655.
7. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308-2314.
8. Hirono S, Mori E, Ikejiri Y etal. Japanese version of the Neuropsychiatric Inventory-assessment of the usefulness of methods of evaluating psychiatric symptoms of dementia. Brain Nerve 1997; 49: 266-271.
9. Zarit SH, Reever KE, Bach-Peterson J. Relatives of the impaired elderly: correlates of feeling of burden. Gerontologist 1980; 20: 649-655.
10. Hirono S, Kobayashi H, Mori E. Burdens on caregivers for dementia patients: Japanese version of the Zarit Caregiver Burden Interview. Brain Nerve 1998; 50: 561-567.
11. Rogers SL, Farlow MR, Doody RS, Mohs R, Fried LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50: 136-145.
12. Burns A, Rossor M, Hecker J etal. The effects of donepezil in Alzheimer's disease-results from a multinational trial. Dement Geriatr Cogn Disord 1999; 10: 237-244.
13. Whitehead A, Perdomo C, Pratt RD, Birks J, Wilcock GK, Evans JG. Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomized controlled trials. Int J Geriatr Psychiatry 2004; 19: 624-633.
14. Holmes C, Wilkinson D, Dean C etal. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004; 63: 214-219.
15. Tanaka T, Kazui H, Morihara T, Sadik G, Kudo T, Takeda M. Post-marketing survey of donepezil hydrochloride in Japanese patients with Alzheimer's disease with behavioral and psychological symptoms of dementia (BPSD). Psychogeriatrics 2008; 8: 114-123.
16. Hori K, Oda T, Tominaga I, Inada T. 'Awakenings' in demented patients. Psychiatry Clin Neurosci 2003; 57: 237.
17. Robert P, Onyike CU, Leentjens AF etal. Proposed diagnostic criteria for apathy in Alzheimer's disease and other neuropsychiatric disorders. Eur Psychiatry 2009; 24: 98-104.
18. Burt T. Donepezil and related cholinesterase inhibitors as mood and behavioral controlling agents. Curr Psychiatry Rep 2000; 2: 473-478.
19. Gauthier S, Feldman H, Hecker J etal. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. Int Psychogeriatr 2002; 14: 389-404.
20. Rodda J, Morgan S, Walker Z. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systemic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. Int Psychogeriatr 2009; 21: 813-824.
21. Hori K, Konishi K, Itagaki T etal. Indications for large-dose anti-dementia drug therapy for Alzheimer's disease-from the standpoint of apathy. Jpn J Psychiatr Treat 2010; 25: 531-538.
22. Germain S, Adam S, Olivier C etal. Does cognitive impairment influence burden in caregivers of patients with Alzheimer's disease? J Alzheimers Dis 2009; 17: 105-114.
23. Nozawa M, Ichimiya Y, Nozawa E etal. Therapeutic effect of large-dose donepezil therapy for Alzheimer's disease. Clin Psychiatr 2008; 50: 975-980.
24. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141: 1356-1364.